AgomAb Therapeutics NV's latest marketcap:
As of 10/14/2026, AgomAb Therapeutics NV's market capitalization has reached $666.23 M. According to our data, AgomAb Therapeutics NV is the 13009th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 666.23 M |
| Revenue (ttm) | 0 |
| Net Income (ttm) | -93,229,750 |
| Shares Out | 48.74 M |
| EPS (ttm) | -4.51 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 11/14/2026 |
AgomAb Therapeutics NV's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 10/16/2026 | $402.34 M | n/a |
Company Profile
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.
The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
Frequently Asked Questions
-
What is AgomAb Therapeutics NV's (AGMB) current market cap?As of 10/14/2026, AgomAb Therapeutics NV (including the parent company, if applicable) has an estimated market capitalization of $666.23 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does AgomAb Therapeutics NV (AGMB) rank globally by market cap?AgomAb Therapeutics NV global market capitalization ranking is approximately 13009 as of 10/14/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.